Bloomberg Intelligence cover image

Novo Halves Ozempic Price to $499 a Month For Those Paying Cash

Bloomberg Intelligence

00:00

Novo Nordisk Secures New Approval for Wegovi Enhancing Market Position

This chapter explores the recent approval of Novo Nordisk's Wegovi for treating MASH, highlighting its potential health benefits and improved insurance coverage prospects. It also examines the competitive landscape with Eli Lilly's ZepBound and the strategic advantages this approval brings to Novo amidst recent challenges.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app